<DOC>
	<DOCNO>NCT00302172</DOCNO>
	<brief_summary>To determine safety , tolerability recommend Phase 2 dose ( RP2D ) ARQ 197 .</brief_summary>
	<brief_title>ARQ 197 Subjects With Metastatic Solid Tumors</brief_title>
	<detailed_description>To determine safety , tolerability recommend Phase 2 dose ( RP2D ) ARQ 197 give orally . This open label , dose escalation study ARQ 197 administer orally start dose 10 mg bid ( 20 mg/day ) .</detailed_description>
	<criteria>Signed write informed consent must obtain document accord ICH GCP , local regulatory requirement , permission use private health information accordance HIPPA prior studyspecific screen procedure A histologically cytologically confirm RCC cMet expression tumor metastatic Patient must available archival tumor tissue accessible tumor safely amenable tumor biopsy ≥ 18 year age Measurable disease define Response Evaluation Criteria Solid Tumors Karnofsky performance status ≥ 70 % Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last ARQ 197 dose Females childbearing potential must negative serum pregnancy test Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 × upper limit normal ( ULN ) ≤ 5.0 × ULN metastatic liver disease . Hemoglobin ( Hgb ) ≥ 10 g/dl Total bilirubin ≤ 1.5 × ULN Creatinine ≤ 1.5 x ULN Absolute neutrophil count ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within four week first dose Surgery within 4 week prior first dose Known brain metastasis Pregnant breastfeed Significant gastrointestinal disorder ( ) , opinion Principal Investigator , ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric resection ) Unable unwilling swallow ARQ 197 capsule twice daily Uncontrolled intercurrent illness include , limited ongoing active infection , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement Bradycardia baseline know history arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>metastatic</keyword>
	<keyword>primary tumor</keyword>
</DOC>